You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 In vitro antimicrobial susceptibility of ESBL producing and ESBL non-producing P. mirabilis isolates

From: The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea

Antimicrobial agent No. (%) of susceptible isolate p value
non-ESBL-producing group N = 48 ESBL producing groupN = 14
Ampicillin 26 (54.2) 1 (7.1) 0.002
Ampicillin/sulbactam 37 (77.1) 4 (28.6) 0.003
Piperacillin/tazobactam 47 (97.9) 12 (100) 0.617
Aztreonam 45 (95.7) 8 (61.5) 0.004
Cefoxitin 42 (87.5) 5 (41.7) 0.002
Cefotaxim 43 (89.6) 3 (23.1) <0.001
Ceftazidime 46 (95.8) 10 (71.4) 0.02
Cefepime 46 (95.8) 4 (28.6) <0.001
Meropenem 44 (91.7) 14 (100) 0.297
Levofloxacin 36 (75.0) 6 (46.2) 0.088
Amikacin 47 (97.9) 11 (78.6) 0.033
Gentamicin 34 (70.8) 3 (21.4) 0.001
Trimethoprim /sulfamethoxazole 29 (60.4) 4 (30.8) 0.057+
  1. ESBL, extended spectrum β-lactamases